Discover the Next Big Biological Breakthrough
Unlike conventional therapeutic pipelines which largely target proteins, we are developing small molecule drugs that prevent disease-causing proteins from ever being made.
The Next Frontier of Drug Discovery
Ribometrix is leading a new drug-discovery paradigm: using small molecules to target RNA biology and prevent the production of proteins that drive disease.
The Ribometrix Difference
Create the Future With Us
We’ve teamed up with strategic partners who are helping us advance the new frontier of direct RNA targeting.
The Potential to Change Lives
When we disrupt the right RBP-RNA interaction, we directly affect function and can help patients fight life-threatening diseases.
Cell Proliferation Disorders
Targeting RNA biology provides us with a unique approach to tackle difficult-to-drug oncogenes.
Central Nervous System
Targeting RNA biology unlocks opportunities to manipulate key nodes of regulation across an array of serious, functionally complex CNS disorders.
Autoimmune Disorders
Targeting RNA biology with small molecules allows us to develop oral drugs for autoimmune diseases and the opportunity to drug intracellular targets inaccessible to biologics.
About Ribometrix
Headquartered in Research Triangle Park, we’ve built the leading industry platform for discovering and developing therapies that modulate RNA biology.
Leaders in Small Molecule Drugs
Our team of RNA experts and drug discovery specialists brings decades of experience to the Ribometrix mission.
Careers
Enjoy a Life-Changing Career at Ribometrix
Cutting-edge technology. Game-changing medical breakthroughs. Working alongside the most passionate scientific leaders in RNA biology. Ribometrix is a unique opportunity to trailblaze the next frontier in drug discovery.
In the Spotlight
The latest news, press and publications from Ribometrix.
-
Ribometrix Present Data Supporting Potential of eIF4E Program in KRAS Mutant Non-Small Cell Lung Cancer at ESMO 2024
-
Ribometrix To Present Data Supporting Potential of eIF4E Program in KRAS Mutant Non-Small Cell Lung Cancer at ESMO 2024
-
Ribometrix Presents First c-MYC Data Validating RNA-Targeting Platform and Demonstrates Synergistic Potential of eIF4E Program at AACR 2024
Connect With Us
For more information, or interest in partnerships, please fill out the form.